Expression and clinical significance of ADAM8 and CEA in serum of patients with non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 11, Issue 6, 2008, Pages 789-792

  Huang, Jinju ^a   Chen, Feipeng ^a   Wu, Yongjian ^a   Yang, Jun ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Enzyme linked immunosorbent assay; Human ADAM8 protein; Human carcinoembryonic antigen; Immunoradiometric assay; Lung neoplasms

Indexed keywords

ADAM PROTEIN; ADAM8 PROTEIN; CARCINOEMBRYONIC ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LUNG ADENOCARCINOMA; LUNG LESION; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

EID: 58549118066     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2008.06.18     Document Type: Article

References (12)

1. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci, 2007, 98(5): 621-628.
2. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev, 2003, 17(1): 7-30.
3. Ishikawa N, Yataro D, Yasui W, et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res, 2004, 10(24): 8363-8370.
4. Rocks N, Paulissen G, Quesada Calvo F, et al. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). British J Cancer, 2006, 94(5): 724-730.
5. Wu GC, Hu HC, Shi MH. Expression and clinical significance of a disintegrin and metalloprotease 8 (ADAM8) and epidermal growth factor receptor (EGFR) in non-small cell lung cancer. Ai zheng, 2008, 27(8): 874-878.
6. Wildeboer D, Naus S, Amy Sang QX, et al. Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol, 2006, 65(5): 516-527.
7. Roemer A, Schwettmann L, Jung M, et al. Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep, 2004, 11(2): 529-536.
8. Valkovskaya N, Kayed H, Felix K, et al. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cell Mol Med, 2007, 11(5): 1162-1174.
9. Ohtsuka T, Shiomi T, Shimoda M, et al. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer, 2006, 118(2): 263-273.
10. Shintani Y, Higashiyama S, Ohta M, et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res, 2004, 64(12): 4190-4196.
11. Hirovuki O, Kazuhiro S, Haruhiko I, et al. Preoperative serum CEA level is predictive for patient outcome in case of non-small cell lung cancer, especially squamous cell carcinoma. Yokohama Med, 2005, 56(5/6): 541-546.
12. Molina R, Filella X, Augé JM, et al. Tumor markers (CEA, CA 125, CYFRA 21.1, SCC and NSE) in non small cell lung cancer (NSCLC) patients as an aid in histological diagnosis and prognosis: Comparison with the main clinical and pathological prognostic factors. Tumour Biol, 2003, 24(4): 209-218.